Getting a Medicare Supplement (Medigap) plan with a cancer diagnosis is entirely possible during your initial enrollment window and straightforward in certain states, but it becomes difficult or impossible in much of the country once that window closes. The outcome hinges on timing, which state you live in, and whether you’re currently in Traditional Medicare or Medicare Advantage. The rules are more tangled than most people expect, and they carry real financial consequences for anyone dealing with cancer treatment costs.
The Federal Open Enrollment Window
Federal law gives every Medicare beneficiary a one-time, six-month open enrollment period for Medigap. It starts the month you turn 65 and are enrolled in Medicare Part B. During this window, insurance companies must sell you any Medigap plan they offer in your state, at the standard price, regardless of your health. A cancer diagnosis, past treatment, ongoing chemotherapy, any of it is irrelevant. Insurers cannot turn you down, charge you more, or impose waiting periods for pre-existing conditions during this period.
This is the single most protective moment in the entire Medigap system. If you are approaching 65 and have cancer or a history of cancer, enrolling during this window is the clearest path to securing a Medigap plan. Missing it can change your options dramatically.
Applying After Open Enrollment Ends
Once your six-month open enrollment period expires, federal protections largely disappear. In most states, Medigap insurers are allowed to use medical underwriting when evaluating your application. That means they can review your health history, ask about current conditions, and decide whether to offer you a policy at all. A cancer diagnosis, whether active or in remission, is one of the most common reasons applications get denied or priced out of reach.
There are a handful of federal “guaranteed issue” rights that kick in under specific circumstances, even outside the initial window. These apply when a triggering event occurs, such as losing employer coverage that supplemented Medicare, or having a Medicare Advantage plan leave your area. In those situations, insurers must sell you certain Medigap plans without medical underwriting. But these rights are narrow and situational. Simply being diagnosed with cancer does not, on its own, trigger a federal guaranteed-issue right.
The practical result is that if you did not buy Medigap during your initial enrollment and you develop cancer afterward, the federal rules alone offer little help in most of the country. This is where state law makes an enormous difference.
States That Offer Stronger Protections
Not every state leaves Medigap access up to medical underwriting after the initial enrollment period. Some states have enacted their own protections that go well beyond the federal floor. Only four states require Medigap policies to be available on a guaranteed-issue basis either continuously or for at least one month per year for all Medicare beneficiaries aged 65 and older. Eight states, including Connecticut, Massachusetts, Maine, Minnesota, New York, Vermont, Washington, and Arkansas, require community rating among policyholders 65 and older, meaning insurers cannot charge higher premiums because someone is older or sicker.1KFF. Medigap Enrollment and Consumer Protections Vary Across States In a community-rated state, an 80-year-old with cancer pays the same Medigap premium as a healthy 66-year-old.
Some states also offer annual open enrollment windows, birthday rules, or anniversary rules that give you a fresh chance to buy or switch Medigap plans without medical underwriting at a set time each year. These vary widely. In Oregon, for instance, you get a window around your birthday. In California, a similar birthday rule applies. If you live in one of these states and have cancer, the annual window can be a genuine lifeline for getting coverage you would otherwise be locked out of.
If you live in a state without these extra protections, though, the landscape is far less forgiving. Most states simply follow the federal minimum: guaranteed issue during your initial enrollment, medical underwriting after that, and no recurring annual windows to reapply without health questions.
The Medicare Advantage Switching Problem
The Medigap access question becomes especially urgent for people enrolled in Medicare Advantage who are diagnosed with cancer. Medicare Advantage plans use provider networks, prior authorization requirements, and other utilization controls that some patients find restrictive once they’re dealing with a complex illness. Traditional Medicare, by contrast, imposes few restrictions on which doctors or hospitals you can see. So it’s not uncommon for someone with a new cancer diagnosis to want to switch from Medicare Advantage to Traditional Medicare, and to want a Medigap policy to fill the gaps in Traditional Medicare’s cost-sharing.2PubMed Central. Medigap Protection and Plan Switching Among Medicare Advantage Enrollees With Cancer
The problem is that switching from Medicare Advantage to Traditional Medicare outside your initial enrollment is a situation where medical underwriting can block your access to Medigap in most states. Researchers have described this as effectively “trapping” cancer patients in Medicare Advantage, because even though you’re technically free to leave, doing so without Medigap leaves you exposed to Traditional Medicare’s coinsurance and deductibles, which can be steep for cancer care.3PubMed Central. State Medigap Policies and Disenrollment From Medicare Advantage Among Beneficiaries With Cancer
The data on this is striking. A 2025 study in JAMA Health Forum tracked what happened when Medicare Advantage enrollees were diagnosed with cancer, comparing states that guarantee Medigap access to those that do not. In states with guaranteed-issue protections, the rate of switching from Medicare Advantage to Traditional Medicare roughly doubled after a cancer diagnosis, jumping from about 2% to nearly 5%. In states without those protections, the switching rate barely moved. The gap between the two groups amounted to about a 120% difference in switching behavior, entirely driven by whether state law made Medigap accessible.2PubMed Central. Medigap Protection and Plan Switching Among Medicare Advantage Enrollees With Cancer People weren’t staying in Medicare Advantage because they preferred it. They were staying because leaving without supplemental coverage was financially unworkable.
There is one federal exception worth knowing about. If you enrolled in Medicare Advantage within your first year of Medicare eligibility and then decide to switch back to Traditional Medicare within 12 months, you have a guaranteed-issue right to buy a Medigap plan. This “trial right” exists specifically for people who tried Medicare Advantage and changed their mind. But if you’ve been in Medicare Advantage for years before your diagnosis, this right no longer applies, and you’re subject to your state’s rules.
What Cancer Care Actually Costs Under Traditional Medicare
Understanding why Medigap matters so much for cancer patients requires looking at what you’d be paying without it. Traditional Medicare covers a lot, but it doesn’t cover everything. You’re responsible for the Part A deductible for hospital stays, 20% coinsurance on Part B outpatient services (with no annual cap), and your share of prescription drug costs under Part D. For routine care, these costs are manageable. For cancer treatment, they can be devastating.
A 2025 analysis of out-of-pocket spending in Traditional Medicare found that beneficiaries with any cancer diagnosis spent an average of roughly $4,800 per year out of pocket in 2023, compared to about $2,364 for beneficiaries without cancer. For certain cancers, the costs were far higher. Multiple myeloma patients faced average annual out-of-pocket costs of about $14,400, acute leukemia patients around $10,500, and those with biliary or liver cancers roughly $9,500 to $9,700. Lung cancer patients spent about $8,600 per year.4Journal of Clinical Oncology. Financial toxicity for cancer patients: Out-of-pocket costs by cancer diagnosis in traditional Medicare Prescription drugs drove a meaningful chunk of those costs for blood cancers in particular, accounting for roughly a fifth of out-of-pocket spending for myeloma and leukemia patients.
Medigap policies are designed to absorb most of this cost-sharing. The most popular plans (Plan F for those who qualified before 2020, and Plan G for those enrolling now) cover the Part B coinsurance entirely, meaning that 20% you’d owe on chemotherapy infusions, radiation sessions, and oncologist visits is picked up by the supplemental plan. Research has found that Traditional Medicare beneficiaries with Medigap had about $1,062 more in total annual Medicare spending than those without Medigap, driven largely by higher outpatient and prescription drug use.5Health Services Research. Use of High- and Low-Value Care Among Traditional Medicare Beneficiaries With and Without Medigap That higher spending reflects, in part, the reality that people with Medigap can afford to actually use their benefits. They’re not skipping appointments or delaying care because of cost concerns.
The trade-off with Medigap is the monthly premium, which typically ranges from about $100 to $300 or more depending on the plan, your age, and your state. For someone facing $10,000 or more in annual cancer-related out-of-pocket costs, though, that premium is usually far less than what they’d pay without it.
How the Inflation Reduction Act Has Changed the Drug Cost Picture
One piece of the financial puzzle has shifted recently. The Inflation Reduction Act, passed in 2022 and phased in over several years, introduced a hard cap on annual out-of-pocket spending under Medicare Part D (the prescription drug benefit). As of 2025, the cap sits at $2,000 per year, regardless of what drugs you take or how expensive they are.
For cancer patients, this is a meaningful change. Before the cap, annual out-of-pocket costs for specialty oral cancer medications ran from about $11,100 to more than $20,500, depending on the drug and how long someone stayed on it. With the 2025 cap, no one pays more than $2,000 for Part D prescriptions in a given year.6PubMed. Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act An estimated 42% of Part D beneficiaries with a cancer diagnosis were projected to have spending above $2,000 without the cap, and for those individuals, the average annual savings were projected at roughly $8,500. Patients with blood cancers stood to save the most, with estimated annual reductions around $10,800 per person.7PubMed. Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer
The Part D cap helps regardless of whether you have Medigap, since Medigap policies generally don’t cover Part D costs anyway (they cover Parts A and B). So even if you can’t get a Medigap plan, the drug cost side of cancer treatment has become substantially more manageable. That said, the cap does nothing about the 20% coinsurance on Part B services like infused chemotherapy, radiation, and surgeon fees, which is exactly where Medigap does its work.
How to Improve Your Chances
If you have cancer and want a Medigap plan, the practical path depends on where you are in the enrollment timeline and where you live. A few strategies can make a real difference.
If you haven’t yet turned 65 and enrolled in Part B, you’re in the best position. Your six-month open enrollment window will give you guaranteed access to any Medigap plan offered in your state, cancer diagnosis or not. Don’t delay enrollment hoping you’ll feel better or that you won’t need it. The window starts automatically, and once it closes, getting that level of access back is difficult in most states.
If you’re already past your open enrollment and live in a state with annual guaranteed-issue windows or birthday rules, find out exactly when your window opens and apply during it. State insurance departments and State Health Insurance Assistance Programs (SHIPs) can tell you your state’s specific rules. These counselors are federally funded, free, and are often the most reliable source of state-specific Medigap information.
If you’re in Medicare Advantage and considering a switch after a cancer diagnosis, check whether your state is one of the handful with Medigap guaranteed-issue protections for switchers. If it is, you can leave Medicare Advantage and pick up a Medigap plan without medical underwriting. If it isn’t, weigh carefully whether the flexibility of Traditional Medicare is worth the exposure to cost-sharing without supplemental coverage. For some patients, staying in Medicare Advantage and working within its network may be financially safer than switching to Traditional Medicare with no Medigap to absorb the coinsurance.
If you’re in a state without extra protections and outside your initial enrollment window, your options narrow but don’t disappear entirely. Some insurers are more lenient with underwriting than others, particularly for cancers that have been in remission for several years. The typical look-back period varies by insurer, but many consider cancer in full remission for five or more years differently than active disease. Applying to multiple insurers is worth the effort, because there is no standardized underwriting threshold across the industry. You might be declined by three companies and approved by a fourth.
When Medigap Isn’t an Option
For people who genuinely cannot obtain a Medigap plan, whether because of medical underwriting, cost, or state rules, there are still ways to manage out-of-pocket exposure under Traditional Medicare. Medicare Savings Programs, administered by state Medicaid offices, can pay your Part B premiums and sometimes cost-sharing if your income and assets fall below certain thresholds. The Extra Help program (also called the Low-Income Subsidy) can reduce Part D drug costs further, stacking on top of the Inflation Reduction Act’s cap.
Many cancer centers also have financial counselors and patient navigators who specialize in identifying assistance programs, including those offered by pharmaceutical manufacturers, nonprofit foundations, and hospital charity care policies. These aren’t substitutes for Medigap, but they can fill gaps that would otherwise translate into skipped treatments or mounting debt. The financial reality for Medicare beneficiaries with cancer varies enormously depending on diagnosis. Someone with early-stage breast cancer may face relatively modest out-of-pocket costs under Traditional Medicare. Someone with multiple myeloma is looking at a fundamentally different financial picture, one where every layer of coverage and assistance matters.4Journal of Clinical Oncology. Financial toxicity for cancer patients: Out-of-pocket costs by cancer diagnosis in traditional Medicare
One emerging policy debate worth watching involves proposals to extend guaranteed-issue Medigap rights nationally, particularly for people leaving Medicare Advantage. Several bills have been introduced in Congress over the past few years that would eliminate medical underwriting for Medigap entirely, or at least create a guaranteed-issue right whenever someone switches from Medicare Advantage back to Traditional Medicare. None have passed as of mid-2025, but the research showing that cancer patients are effectively trapped in plans they’d prefer to leave has added urgency to the conversation.3PubMed Central. State Medigap Policies and Disenrollment From Medicare Advantage Among Beneficiaries With Cancer Whether or not federal law changes, understanding your current state’s rules remains the most immediately useful thing you can do.